Reports Q3 revenue $785M, consensus $773.81M. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio. CREXONT for Parkinson’s disease and other key branded products continue to drive Specialty growth, complemented by the launch this month of BREKIYA in the migraine space. At the same time, our Affordable Medicines segment is entering a significant new product launch cycle, with multiple complex approvals this quarter and numerous new key launches expected ahead. Together with our recent refinancing, Amneal is closing 2025 and entering 2026 from a position of strength and momentum,” said Chirag and Chintu Patel, Co-CEOs.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal gets FDA approval for beclomethasone dipropionate HFA inhalation aerosol
- Mycophenolate Pregnancy Registry: Key Insights for Investors
- Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?
- Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
- Amneal treatment of known or suspected cyanide poisoning granted orphan status